Company intelligence / Profile preview
GlycoNex
New Taipei City, Taiwanglyconex.com.tw ↗
- Ownership
- Public · 4168
- Development stage
- Preclinical
01
Overview
GlycoNex has completed Phase 1 trials for its lead monoclonal antibody GNX102 with excellent safety and promising efficacy. Its ADC candidate GNX1021 has shown potent tumor inhibition in preclinical gastric cancer models and is advancing toward IND-enabling studies. The company also has a denosumab biosimilar in Phase 3 clinical trials.
- Therapeutic areas
- OphthalmologyOncologyEndocrinology
- Modalities
- Monoclonal antibodyAntibody-drug conjugateRecombinant fusion proteinSmall molecule
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
PrecisemAb (technology licensing agreement for Universal Antibody Lock)
04
Financials
- Market cap
- $68.5M
- Total revenue
- $1.2M
- Enterprise value
- $65.8M
Beyond the preview
Go deeper on GlycoNex.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GlycoNex.